Dashboard

Failed primary endpoint in a pivotal ambulatory DMD cohort raises questions about clinical efficacy and may affect regulatory confidence in extension cohorts (Cohort 8 non-ambulatory). This directly impacts the regulatory score and market positioning for Elevidys post-approval.

This is the pivotal Phase 3 trial supporting the ambulatory DMD approval. Primary endpoint failure raises questions about clinical benefit durability and regulatory scrutiny for non-ambulatory expansion (Cohort 8). Contradicts strength of regulatory score (3) if approval was based on marginal primary efficacy.

This is the pivotal Phase 3 trial supporting the ambulatory DMD approval. Primary endpoint failure raises questions about clinical benefit durability and regulatory scrutiny for non-ambulatory expansion (Cohort 8). Contradicts strength of regulatory score (3) if approval was based on marginal primary efficacy.

Critical discrepancy: The asset is described as 'Approved but withdrawing by May 2026' yet openFDA (Tier 1) returns zero approvals and zero designations for BioMarin. This contradicts the claimed regulatory status. If Roctavian were genuinely FDA-approved, it would appear in openFDA records. Absence of any approvals or designations suggests either: (1) the product was never approved, (2) the approval was conditional/limited and later withdrawn, or (3) the company name/product name mismatch in the database.

RP1 is re-evaluated from first principles following receipt of a second CRL, which materially worsens the regulatory outlook. **Regulatory (1/5):** Two CRLs signal persistent, unresolved deficiencies — likely CMC/manufacturing-related given prior disclosures. No resubmission timeline has been announced. A score of 1 reflects a weak but not fully failed pathway; the program is not terminated and no clinical hold exists, but the regulatory trajectory is severely impaired. A score of 0 would require outright failure or formal withdrawal. **Commercial Infrastructure (1/5):** Replimune has not built meaningful commercial infrastructure. With no approved product and no clear approval timeline, there is no sales force, distribution network, or launch readiness. Score of 1 reflects a small-cap biotech with no commercial operations. **Market Attractiveness (3/5):** Advanced melanoma remains a meaningful oncolytic virus opportunity. The anti-PD-1 refractory/combination niche is commercially relevant, and T-VEC (Imlygic) withdrawal from US market leaves a gap. However, checkpoint inhibitor combinations (nivo+ipi, LAG-3 combos) and emerging therapies (TIL therapy lifileucel) create a competitive and evolving landscape. Moderate attractiveness, not high-value/low-barrier. **Capability Gap Leverage (1/5):** The manufacturing pathway remains unclear — a critical structural barrier for an oncolytic virus therapy. Two CRLs suggest the company has not been able to resolve CMC gaps. Without a viable manufacturing solution, there is minimal leverage for a potential acquirer or partner to unlock value. The clinical data (CERPASS results) showed some activity, but the inability to convert to an approvable BLA severely constrains leverage. Score of 1 reflects a weak asset position with largely unsolvable gaps in the near term. **Overall:** This asset remains in a deeply challenged position. Two CRLs, no manufacturing resolution, no resubmission timeline, and no commercial readiness place it firmly in a low-priority tier. The no_manufacturing_pathway and timeline_over_24_months flags remain triggered. The no_us_path flag is not triggered because the program is not formally abandoned — a path theoretically exists but is highly uncertain.

RP1 is re-evaluated from first principles following receipt of a second CRL, which materially worsens the regulatory outlook. **Regulatory (1/5):** Two CRLs signal persistent, unresolved deficiencies — likely CMC/manufacturing-related given prior disclosures. No resubmission timeline has been announced. A score of 1 reflects a weak but not fully failed pathway; the program is not terminated and no clinical hold exists, but the regulatory trajectory is severely impaired. A score of 0 would require outright failure or formal withdrawal. **Commercial Infrastructure (1/5):** Replimune has not built meaningful commercial infrastructure. With no approved product and no clear approval timeline, there is no sales force, distribution network, or launch readiness. Score of 1 reflects a small-cap biotech with no commercial operations. **Market Attractiveness (3/5):** Advanced melanoma remains a meaningful oncolytic virus opportunity. The anti-PD-1 refractory/combination niche is commercially relevant, and T-VEC (Imlygic) withdrawal from US market leaves a gap. However, checkpoint inhibitor combinations (nivo+ipi, LAG-3 combos) and emerging therapies (TIL therapy lifileucel) create a competitive and evolving landscape. Moderate attractiveness, not high-value/low-barrier. **Capability Gap Leverage (1/5):** The manufacturing pathway remains unclear — a critical structural barrier for an oncolytic virus therapy. Two CRLs suggest the company has not been able to resolve CMC gaps. Without a viable manufacturing solution, there is minimal leverage for a potential acquirer or partner to unlock value. The clinical data (CERPASS results) showed some activity, but the inability to convert to an approvable BLA severely constrains leverage. Score of 1 reflects a weak asset position with largely unsolvable gaps in the near term. **Overall:** This asset remains in a deeply challenged position. Two CRLs, no manufacturing resolution, no resubmission timeline, and no commercial readiness place it firmly in a low-priority tier. The no_manufacturing_pathway and timeline_over_24_months flags remain triggered. The no_us_path flag is not triggered because the program is not formally abandoned — a path theoretically exists but is highly uncertain.

Vigil remains a challenging asset from a licensing/partnering perspective. Re-deriving from first principles: **Regulatory (2/5):** The Phase 3 VITAL trial has generated overall survival data presented at ASCO (hazard ratio favoring Vigil in BRCA wild-type subgroup), but Gradalis has not announced a BLA filing timeline, FDA breakthrough or fast-track designation, or pre-BLA meeting. The data, while encouraging in a subgroup, has not yet been characterized as registrational-grade by the company or FDA. The trial enrolled ~91 patients, which is small, and the primary endpoint results and regulatory path remain ambiguous. Score of 2 reflects early Phase 3 with uncertain regulatory trajectory. **Commercial Infrastructure (1/5):** Gradalis is a small, privately held company based in Dallas, TX with no disclosed commercial team, no sales force, no market access infrastructure, and no announced commercial partnerships. There is essentially no commercial buildout. Score of 1. **Market Attractiveness (3/5):** Ovarian cancer frontline maintenance is a meaningful market, though increasingly competitive (PARP inhibitors — olaparib, niraparib, rucaparib — dominate, especially in HRD+ populations). Vigil's niche is the BRCA wild-type / HRD-negative population, which is underserved and represents a real unmet need. However, the autologous, personalized manufacturing model severely constrains addressable patient volume and margin potential. Score of 3 reflects moderate attractiveness tempered by manufacturing constraints. **Capability Gap Leverage (2/5):** The autologous manufacturing model (tumor harvest → electroporation → cryopreservation → return to patient) is inherently difficult to scale and requires a highly specialized supply chain. No CDMO partnerships or manufacturing scale-up plans have been publicly disclosed. While the mechanism is differentiated, the practical barriers to commercialization are substantial and it is unclear if a partner could solve these gaps within a reasonable timeframe. Score of 2. **Overall:** Vigil is scientifically interesting with a differentiated mechanism in an underserved population, but the combination of a small private company with no commercial infrastructure, unclear BLA timeline, and challenging autologous manufacturing makes this a lower-tier opportunity. The >24-month timeline flag remains firmly set.

Vigil remains a challenging asset from a licensing/partnering perspective. Re-deriving from first principles: **Regulatory (2/5):** The Phase 3 VITAL trial has generated overall survival data presented at ASCO (hazard ratio favoring Vigil in BRCA wild-type subgroup), but Gradalis has not announced a BLA filing timeline, FDA breakthrough or fast-track designation, or pre-BLA meeting. The data, while encouraging in a subgroup, has not yet been characterized as registrational-grade by the company or FDA. The trial enrolled ~91 patients, which is small, and the primary endpoint results and regulatory path remain ambiguous. Score of 2 reflects early Phase 3 with uncertain regulatory trajectory. **Commercial Infrastructure (1/5):** Gradalis is a small, privately held company based in Dallas, TX with no disclosed commercial team, no sales force, no market access infrastructure, and no announced commercial partnerships. There is essentially no commercial buildout. Score of 1. **Market Attractiveness (3/5):** Ovarian cancer frontline maintenance is a meaningful market, though increasingly competitive (PARP inhibitors — olaparib, niraparib, rucaparib — dominate, especially in HRD+ populations). Vigil's niche is the BRCA wild-type / HRD-negative population, which is underserved and represents a real unmet need. However, the autologous, personalized manufacturing model severely constrains addressable patient volume and margin potential. Score of 3 reflects moderate attractiveness tempered by manufacturing constraints. **Capability Gap Leverage (2/5):** The autologous manufacturing model (tumor harvest → electroporation → cryopreservation → return to patient) is inherently difficult to scale and requires a highly specialized supply chain. No CDMO partnerships or manufacturing scale-up plans have been publicly disclosed. While the mechanism is differentiated, the practical barriers to commercialization are substantial and it is unclear if a partner could solve these gaps within a reasonable timeframe. Score of 2. **Overall:** Vigil is scientifically interesting with a differentiated mechanism in an underserved population, but the combination of a small private company with no commercial infrastructure, unclear BLA timeline, and challenging autologous manufacturing makes this a lower-tier opportunity. The >24-month timeline flag remains firmly set.